Search results

1324 results

Sorted by Relevance . Sort by Date

  1. Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis (TA127)

    Evidence-based recommendations on natalizumab (Tysabri) for highly active relapsing–remitting multiple sclerosis (MS) in adults

  2. Inhaled corticosteroids for the treatment of chronic asthma in children under the age of 12 years (TA131)

    Evidence-based recommendations on inhaled corticosteroids (ICSs) for chronic asthma in children aged under 12

  3. Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura (TA293)

    Evidence-based recommendations on eltrombopag (Revolade) for treating chronic immune (idiopathic) thrombocytopenic purpura (chronic ITP)

  4. Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy (TA301)

    Evidence-based recommendations on fluocinolone acetonide intravitreal implant (Iluvien) for chronic diabetic macular oedema after prior therapy

  5. Teriflunomide for treating relapsing–remitting multiple sclerosis (TA303)

    Evidence-based recommendations on teriflunomide (Aubagio) for treating relapsing–remitting multiple sclerosis (RRMS/MS) in adults

  6. Total hip replacement and resurfacing arthroplasty for end-stage arthritis of the hip (TA304)

    Evidence-based recommendations on total hip replacement and resurfacing arthroplasty for treating end-stage arthritis of the hip

  7. Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion (TA305)

    Evidence-based recommendations on aflibercept (Eylea) for visual impairment caused by macular oedema secondary to central retinal vein occlusion

  8. Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failure (TA314)

    Evidence-based recommendations on implantable cardioverter defibrillators (ICDs) and cardiac resynchronisation therapy (CRT) for arrhythmias and heart failure

  9. Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes (TA317)

    Evidence-based recommendations on prasugrel (Efient) with percutaneous coronary intervention (PCI) for treating acute coronary syndrome (ACS)

  10. Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy (TA307)

    Evidence-based recommendations on aflibercept (Zaltrap) with FOLFIRI for metastatic colorectal cancer that has progressed after oxaliplatin

  11. Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis (TA308)

    Evidence-based recommendations on rituximab (MabThera) with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis

  12. Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer (TA310)

    Evidence-based recommendations on afatinib (Giotrif) for treating EGFR-TK mutation-positive locally advanced or metastatic non-small-cell lung cancer..

  13. Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation (TA311)

    Evidence-based recommendations on bortezomib (Velcade) for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell..

  14. Ocriplasmin for treating vitreomacular traction (TA297)

    Evidence-based recommendations on ocriplasmin (Jetrea) for treating vitreomacular traction in adults

  15. Ranibizumab for treating choroidal neovascularisation associated with pathological myopia (TA298)

    Evidence-based recommendations on ranibizumab (Lucentis) for treating choroidal neovascularisation associated with pathological myopia

  16. Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people (TA300)

    Evidence-based recommendations on peginterferon alfa and ribavirin (Pegasys) for treating chronic hepatitis C in children and young people

  17. Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer (TA638)

    Evidence-based recommendations on atezolizumab (Tecentriq) for untreated extensive-stage small-cell lung cancer in adults

  18. Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder (TA292)

    Evidence-based recommendations on aripiprazole (Abilify) for treating moderate to severe manic episodes in adolescents with bipolar I disorder

  19. Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure (TA617)

    Evidence-based recommendations on lusutrombopag (Mulpleo) for severe thrombocytopenia in adults with chronic liver disease needing a planned invasive procedure

  20. Everolimus for preventing organ rejection in liver transplantation (TA348)

    Evidence-based recommendations on everolimus (Certican) for preventing organ rejection in people having a liver transplant

  21. Dexamethasone intravitreal implant for treating diabetic macular oedema (TA349)

    Evidence-based recommendations on dexamethasone intravitreal implant (Ozurdex) for treating diabetic macular oedema

  22. Secukinumab for treating moderate to severe plaque psoriasis (TA350)

    Evidence-based recommendations on secukinumab (Cosentyx) for treating moderate to severe plaque psoriasis

  23. Guidance on the use of ultrasound locating devices for placing central venous catheters (TA49)

    Evidence-based recommendations on ultrasound locating devices for placing central venous catheters into the internal jugular vein

  24. Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity (TA589)

    Evidence-based recommendations on blinatumomab (Blincyto) for treating Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia

  25. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (TA195)

    Evidence-based recommendations on adalimumab, etanercept, infliximab, rituximab and abatacept for treating rheumatoid arthritis after failure of a TNF inhibitor

  26. Certolizumab pegol for treating moderate to severe plaque psoriasis (TA574)

    Evidence-based recommendations on certolizumab pegol (Cimzia) for treating moderate to severe plaque psoriasis in adults

  27. Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome (TA615)

    Evidence-based recommendations on cannabidiol (Epidyolex) with clobazam for seizures associated with Lennox–Gastaut syndrome in people aged 2 years and older

  28. Cannabidiol with clobazam for treating seizures associated with Dravet syndrome (TA614)

    Evidence-based recommendations on cannabidiol (Epidyolex) with clobazam for seizures associated with Dravet syndrome (DS) in people aged 2 years and older

  29. Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab (TA612)

    Evidence-based recommendations on neratinib (Nerlynx) for extended adjuvant treatment of hormone receptor-positive, human epidermal growth factor receptor 2

  30. Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease (TA607)

    Evidence-based recommendations on rivaroxaban (Xarelto) for preventing atherothrombotic events in adults with coronary or peripheral artery disease